Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1994 Feb;62(2):692–696. doi: 10.1128/iai.62.2.692-696.1994

Interleukin-6 (IL-6) production in mice infected with Trypanosoma cruzi: effect of its paradoxical increase by anti-IL-6 monoclonal antibody treatment on infection and acute-phase and humoral immune responses.

C Truyens 1, A Angelo-Barrios 1, F Torrico 1, J Van Damme 1, H Heremans 1, Y Carlier 1
PMCID: PMC186159  PMID: 8300226

Abstract

Trypanosoma cruzi infection of mice triggered endogenous production of interleukin-6 (IL-6) during the ascending phase of parasitemia. Injections of anti-IL-6 monoclonal antibody in infected mice at the time of the serum IL-6 peak paradoxically increased IL-6 levels to 60- to 80-fold those in infected mice receiving unrelated immunoglobulins. This early and transient increase in circulating IL-6 levels modified neither the immunoglobulin nor T. cruzi-specific antibody levels of immunoglobulin G1 (IgG1), IgG2a, IgG3, IgM, IgA, and IgE isotypes or the final outcome of infection nor the blood or tissular parasite levels. However, it tended to delay mortality of mice and to increase the levels of the acute-phase protein serum amyloid P component.

Full text

PDF
692

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993;54:1–78. doi: 10.1016/s0065-2776(08)60532-5. [DOI] [PubMed] [Google Scholar]
  2. Carlier Y., Rivera M. T., Truyens C., Puissant F., Milaire J. Interactions between chronic murine Trypanosoma cruzi infection and pregnancy: fetal growth retardation. Am J Trop Med Hyg. 1987 Nov;37(3):534–540. doi: 10.4269/ajtmh.1987.37.534. [DOI] [PubMed] [Google Scholar]
  3. Cayphas S., Van Damme J., Vink A., Simpson R. J., Billiau A., Van Snick J. Identification of an interleukin HP1-like plasmacytoma growth factor produced by L cells in response to viral infection. J Immunol. 1987 Nov 1;139(9):2965–2969. [PubMed] [Google Scholar]
  4. D'Imperio Lima M. R., Joskowicz M., Coutinho A., Kipnis T., Eisen H. Very large and isotypically atypical polyclonal plaque-forming cell responses in mice infected with Trypanosoma cruzi. Eur J Immunol. 1985 Feb;15(2):201–203. doi: 10.1002/eji.1830150219. [DOI] [PubMed] [Google Scholar]
  5. Finkelman F. D., Madden K. B., Morris S. C., Holmes J. M., Boiani N., Katona I. M., Maliszewski C. R. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol. 1993 Aug 1;151(3):1235–1244. [PubMed] [Google Scholar]
  6. Goldberg S. S., Cordeiro M. N., Silva Pereira A. A., Mares-Guia M. L. Release of lipopolysaccharide (LPS) from cell surface of Trypanosoma cruzi by EDTA. Int J Parasitol. 1983 Feb;13(1):11–18. doi: 10.1016/s0020-7519(83)80062-9. [DOI] [PubMed] [Google Scholar]
  7. Grau G. E., Frei K., Piguet P. F., Fontana A., Heremans H., Billiau A., Vassalli P., Lambert P. H. Interleukin 6 production in experimental cerebral malaria: modulation by anticytokine antibodies and possible role in hypergammaglobulinemia. J Exp Med. 1990 Nov 1;172(5):1505–1508. doi: 10.1084/jem.172.5.1505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Heremans H., Dillen C., Put W., Van Damme J., Billiau A. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur J Immunol. 1992 Sep;22(9):2395–2401. doi: 10.1002/eji.1830220932. [DOI] [PubMed] [Google Scholar]
  9. Kern P., Hemmer C. J., Van Damme J., Gruss H. J., Dietrich M. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med. 1989 Aug;87(2):139–143. doi: 10.1016/s0002-9343(89)80688-6. [DOI] [PubMed] [Google Scholar]
  10. Libert C., Vink A., Coulie P., Brouckaert P., Everaerdt B., Van Snick J., Fiers W. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. Eur J Immunol. 1992 Oct;22(10):2625–2630. doi: 10.1002/eji.1830221023. [DOI] [PubMed] [Google Scholar]
  11. Lin B. F., Ku N. O., Zahedi K., Whitehead A. S., Mortensen R. F. IL-1 and IL-6 mediate increased production and synthesis by hepatocytes of acute-phase reactant mouse serum amyloid P-component (SAP). Inflammation. 1990 Jun;14(3):297–313. doi: 10.1007/BF00915814. [DOI] [PubMed] [Google Scholar]
  12. Lu Z. Y., Brochier J., Wijdenes J., Brailly H., Bataille R., Klein B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol. 1992 Nov;22(11):2819–2824. doi: 10.1002/eji.1830221110. [DOI] [PubMed] [Google Scholar]
  13. Martens E., Dillen C., Put W., Heremans H., van Damme J., Billiau A. Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes. Eur J Immunol. 1993 Aug;23(8):2026–2029. doi: 10.1002/eji.1830230846. [DOI] [PubMed] [Google Scholar]
  14. Mortensen R. F., Beisel K., Zeleznik N. J., Le P. T. Acute-phase reactants of mice. II. Strain dependence of serum amyloid P-component (SAP) levels and response to inflammation. J Immunol. 1983 Feb;130(2):885–889. [PubMed] [Google Scholar]
  15. Scharfstein J., Barcinski M. A., Leon L. L. Induction of the acute-phase protein serum amyloid P in experimental Chagas' disease. Infect Immun. 1982 Jan;35(1):46–51. doi: 10.1128/iai.35.1.46-51.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schlüter D., Deckert-Schlüter M., Schwendemann G., Brunner H., Hof H. Expression of major histocompatibility complex class II antigens and levels of interferon-gamma, tumour necrosis factor, and interleukin-6 in cerebrospinal fluid and serum in Toxoplasma gondii-infected SCID and immunocompetent C.B-17 mice. Immunology. 1993 Mar;78(3):430–435. [PMC free article] [PubMed] [Google Scholar]
  17. Stadnyk A., Gauldie J. The acute phase protein response during parasitic infection. Immunol Today. 1991 Mar;12(3):A7–12. doi: 10.1016/s0167-5699(05)80004-0. [DOI] [PubMed] [Google Scholar]
  18. Starnes H. F., Jr, Pearce M. K., Tewari A., Yim J. H., Zou J. C., Abrams J. S. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol. 1990 Dec 15;145(12):4185–4191. [PubMed] [Google Scholar]
  19. Tanowitz H. B., Gumprecht J. P., Spurr D., Calderon T. M., Ventura M. C., Raventos-Suarez C., Kellie S., Factor S. M., Hatcher V. B., Wittner M. Cytokine gene expression of endothelial cells infected with Trypanosoma cruzi. J Infect Dis. 1992 Sep;166(3):598–603. doi: 10.1093/infdis/166.3.598. [DOI] [PubMed] [Google Scholar]
  20. Titus R. G., Sherry B., Cerami A. The involvement of TNF, IL-1 and IL-6 in the immune response to protozoan parasites. Immunol Today. 1991 Mar;12(3):A13–A16. doi: 10.1016/S0167-5699(05)80005-2. [DOI] [PubMed] [Google Scholar]
  21. Torrico F., Heremans H., Rivera M. T., Van Marck E., Billiau A., Carlier Y. Endogenous IFN-gamma is required for resistance to acute Trypanosoma cruzi infection in mice. J Immunol. 1991 May 15;146(10):3626–3632. [PubMed] [Google Scholar]
  22. Van Damme J., Schaafsma M. R., Fibbe W. E., Falkenburg J. H., Opdenakker G., Billiau A. Simultaneous production of interleukin 6, interferon-beta and colony-stimulating activity by fibroblasts after viral and bacterial infection. Eur J Immunol. 1989 Jan;19(1):163–168. doi: 10.1002/eji.1830190126. [DOI] [PubMed] [Google Scholar]
  23. Van Snick J., Cayphas S., Vink A., Uyttenhove C., Coulie P. G., Rubira M. R., Simpson R. J. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9679–9683. doi: 10.1073/pnas.83.24.9679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990;8:253–278. doi: 10.1146/annurev.iy.08.040190.001345. [DOI] [PubMed] [Google Scholar]
  25. Van Voorhis W. C. Coculture of human peripheral blood mononuclear cells with Trypanosoma cruzi leads to proliferation of lymphocytes and cytokine production. J Immunol. 1992 Jan 1;148(1):239–248. [PubMed] [Google Scholar]
  26. Vink A., Coulie P., Warnier G., Renauld J. C., Stevens M., Donckers D., Van Snick J. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J Exp Med. 1990 Sep 1;172(3):997–1000. doi: 10.1084/jem.172.3.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wendling D., Racadot E., Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol. 1993 Feb;20(2):259–262. [PubMed] [Google Scholar]
  28. el Bouhdidi A., Truyens C., Rivera M. T., Bazin H., Carlier Y. Trypanosoma cruzi infection in mice induces a polyisotypic hypergammaglobulinaemia and parasite-specific response involving high IgG2a concentrations and highly avid IgG1 antibodies. Parasite Immunol. 1994 Feb;16(2):69–76. doi: 10.1111/j.1365-3024.1994.tb00325.x. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES